-
Looking For Leftover Value in Nivalis Following Drug Trial Miss
Tuesday, November 29, 2016 - 2:50pm | 378Read More...At a time when Nivalis Therapeutics Inc (NASDAQ: NVLS) is being thrashed with multiple downgrades, H.C. Wainwright maintains its Buy rating, despite the announcement of a trial miss. Trial Miss And Share Reaction Shares of Nivalis plunged to a new 52-week low of $2.58 after it reported that the...
-
Vertex Pharmaceuticals Relapses To A Neutral Rating At H.C. Wainwright
Monday, October 24, 2016 - 9:06am | 382Read More...H.C. Wainwright & Co. downgraded shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) from Buy to a Neutral rating citing that fundamentals are not holding up. The firm also slashed its target price from $155 to $85 on the stock implying about 5 percent upside potentials from the...
-
Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64
Tuesday, August 30, 2016 - 12:16pm | 552Read More...Janney has initiated coverage of Galapagos NV (ADR) (NASDAQ: GLPG) with a Buy rating and fair value estimate of $64, citing potential success of Filgotinib. Galapagos has deals with Gilead Sciences, Inc. (NASDAQ: GILD) and AbbVie Inc (NYSE: ABBV) for the development of Filgotinib in inflammatory...
-
Oppenheimer Incrementally More Bullish on Gilead, Remains Cautious On Vertex
Tuesday, October 20, 2015 - 12:00pm | 622Read More...Wendy Lam of Oppenheimer maintained an Outperform rating on shares of Gilead Sciences, Inc. (NASDAQ: GILD) and Perform rating on shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Lam noted that Gilead's two core franchises offer a "durable foundation" of substantial...
-
Goldman Comments On Vertex Pharmaceuticals Following FDA Approval
Thursday, July 2, 2015 - 1:41pm | 242Read More...Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) were trading higher by nearly 4 percent on Thursday after the FDA approved the company's Orkambi (lumacafor/ivacaftor) for the treatment of cystic fibrosis patients 12 years and older. Commenting on the FDA's approval, Terence Flynn, PhD...
-
Vertex Shares Rally As FDA Panel Backs Orkambi; HC Wainwright Analyst Offers Thoughts
Wednesday, May 13, 2015 - 10:26am | 419Read More...H.C. Wainwright commented on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Wednesday following the FDA AdCom endorsement to approve Orkambi as the stock surged over 5 percent in pre-market trading. Analyst Andrew S. Fein believed that since the Phase 3 win and going into the AdCom, “...
